

ETOPOSIDE oral

INDICATION (ICD10) C56

1. Platinum resistant or relapsed ovarian cancer. PS 0, 1, 2

REGIMEN

Days 1 to 14	ETOPOSIDE	100mg*	oral	once daily*
--------------	------------------	--------	------	-------------

*dose may be given as 50mg twice daily to improve tolerability

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 21 days for up to 6 cycles

If it follows 2 cycles of cisplatin etoposide oral regimen then up to 4 cycles

ADMINISTRATION

Available as 50mg and 100mg capsules

Take on an empty stomach

ANTI-EMETICS

Low emetic risk days 1 to 14

CONCURRENT MEDICATION REQUIRED

Etoposide	None required
-----------	---------------

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs Neutrophils x 10 ⁹ /L ≥1.0 provided patient is well Platelets ≥100x10 ⁹ /L	baseline and every cycle
Calculated creatinine clearance at the Consultant's discretion	baseline and every cycle
Serum creatinine	baseline and every cycle
CA125	baseline and day 1 every cycle or as required
Virology	before cycle 1 if not previously checked
Weight	baseline and every cycle

MAIN TOXICITIES AND ADVERSE REACTIONS

Etoposide	-
-----------	---

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stockleys)

Etoposide	-
-----------	---

DOSE MODIFICATIONS

Hepatic impairment

Etoposide

Bilirubin ≥50micromol/L or decreased albumin	give 50% dose
--	---------------

Renal impairment

Etoposide

CrCl >50ml/min	give 100% dose
CrCl 15-50ml/min	give 75% dose
CrCl <15ml/min	Further dose reduction

REFERENCES

Assessments

	Pre	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Ongoing
Clinical assessment	X		Pre cycle		Pre cycle	Every cycle
SACT assessment (PS and toxicities)	X	X	X	X	X	Every cycle
FBC	X	X	X	X	X	Every cycle
U&E, calcium & LFT	X	X	X	X	X	Every cycle
CA125	X	X	X	X	X	Every cycle as required
CrCl	X	X	X	X	X	Every cycle
CT scan	X					At cycle 6, Inform consultant team if not booked
Informed consent	X					Verbal each cycle
Height	X					
Weight recorded	X	X	X	X	X	Every cycle